<!DOCTYPE html>
<html>
<head>
	<meta http-equiv="content-type" content="text/html; charset=utf-8"/>
	<title></title>
	<meta name="generator" content="LibreOffice 7.3.1.3 (Linux)"/>
	<meta name="created" content="2023-10-26T20:27:08.823352696"/>
	<meta name="changed" content="2023-11-14T11:32:06.199669923"/>
	<style type="text/css">
		@page { size: 8.5in 11in; margin: 0.79in }
		p { line-height: 115%; margin-bottom: 0.1in; background: transparent; background: transparent }
		h1 { margin-bottom: 0.08in; background: transparent; background: transparent; page-break-after: avoid }
		h1.western { font-family: "Liberation Serif", serif; font-size: 24pt; font-weight: bold }
		h1.cjk { font-family: "Noto Serif CJK SC"; font-size: 24pt; font-weight: bold }
		h1.ctl { font-family: "Lohit Devanagari"; font-size: 24pt; font-weight: bold }
		h4 { margin-top: 0.08in; margin-bottom: 0.08in; background: transparent; background: transparent; page-break-after: avoid }
		h4.western { font-family: "Liberation Serif", serif; font-size: 12pt; font-weight: bold }
		h4.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; font-weight: bold }
		h4.ctl { font-family: "Lohit Devanagari"; font-size: 12pt; font-weight: bold }
		h5 { margin-top: 0.08in; margin-bottom: 0.04in; background: transparent; background: transparent; page-break-after: avoid }
		h5.western { font-family: "Liberation Serif", serif; font-size: 10pt; font-weight: bold }
		h5.cjk { font-family: "Noto Serif CJK SC"; font-size: 10pt; font-weight: bold }
		h5.ctl { font-family: "Lohit Devanagari"; font-size: 10pt; font-weight: bold }
		strong { font-weight: bold }
		a:link { color: #000080; so-language: zxx; text-decoration: underline }
		a:visited { color: #800000; so-language: zxx; text-decoration: underline }
	</style>
</head>
<body lang="en-US" link="#000080" vlink="#800000" dir="ltr"><h1 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in">
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><b>ACC/AHA
Guidelines for the Management of Patients With Unstable Angina and
Non–ST-Segment Elevation Myocardial Infarction: Executive Summary
and Recommendations</b></font></font></font></h1>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-bottom: 0in">
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">A
Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on the
Management of Patients With Unstable Angina)</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-bottom: 0in">
<br/>

</p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
I:&nbsp;Conditions for which there is evidence and/or general
agreement that a given procedure or treatment is useful and
effective</b></i></span></font></font></font></span></strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">.</span></span></span></font></font></font></span></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
II:&nbsp;Conditions for which there is conflicting evidence and/or a
divergence of opinion about the usefulness/efficacy of a procedure or
treatment.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
IIa:&nbsp;Weight of evidence/opinion is in favor of
usefulness/efficacy.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
IIb:&nbsp;Usefulness/efficacy is less well established by
evidence/opinion.</b></i></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><i><b>Class
III:&nbsp;Conditions for which there is evidence and/or general
agreement that the procedure/treatment is not useful/effective and in
some cases may be harmful.</b></i></span></font></font></font></span></strong></p>
<h4 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e437"></a>
<span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>A.
Clinical Assessment</b></span></span></font></font></font></span></h4>
<h5 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in">
<br/>

</h5>
<h5 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e441"></a>
<span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Class
I</span></span></span></font></font></font></span></h5>
<p style="orphans: 2; widows: 2; margin-bottom: 0in"><br/>

</p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Patients with symptoms that suggest possible ACS should not be
evaluated solely over the telephone but should be referred to a
facility that allows evaluation by a physician and the recording of a
12-lead electrocardiogram (ECG). (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients with a suspected ACS with chest discomfort at rest for &gt;20
minutes, hemodynamic instability, or recent syncope or presyncope
should be strongly considered for immediate referral to an emergency
department (ED) or a specialized chest pain unit. Other patients with
a suspected ACS may be seen initially in an ED, a chest pain unit, or
an outpatient facility. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<h4 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e452"></a>
<span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>B.
Early Risk Stratification</b></span></span></font></font></font></span></h4>
<h5 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in">
<br/>

</h5>
<h5 class="western" style="orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e456"></a>
<span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Class
I</span></span></span></font></font></font></span></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
A determination of the likelihood (high, intermediate, or low) of
acute ischemia caused by CAD should be made in all patients with
chest discomfort. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>2.
Patients who present with chest discomfort should undergo early risk
stratification that focuses on anginal symptoms, physical findings,
ECG findings, and biomarkers of cardiac injury. (Level of Evidence:
B)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>3.
A 12-lead ECG should be obtained immediately (within 10 minutes) in
patients with ongoing chest discomfort and as rapidly as possible in
patients who have a history of chest discomfort consistent with ACS
but whose discomfort has resolved by the time of evaluation. (Level
of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>4.
Biomarkers of cardiac injury should be measured in all patients who
present with chest discomfort consistent with ACS. A cardiac-specific
troponin is the preferred marker, and if available, it should be
measured in all patients. CK-MB by mass assay is also acceptable. In
patients with negative cardiac markers within 6 hours of the onset of
pain, another sample should be drawn in the 6- to 12-hour time frame
(eg, at 9 hours after the onset of symptoms). (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e477" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e477"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIa</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
For patients who present within 6 hours of the onset of symptoms, an
early marker of cardiac injury (eg, myoglobin or CK-MB subforms)
should be considered in addition to a cardiac troponin. (Level of
Evidence: C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e484" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e484"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
IIb</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
C-reactive protein(CRP) and other markers of inflammation should be
measured. (Level of Evidence: B)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e491" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e491"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
III</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
Total CK (without MB), aspartate aminotransferase (AST,
SGOT),β-hydroxybutyric dehydrogenase, and/or lactate dehydrogenase
should be the marker for the detection of myocardial injury in
patients with chest discomfort suggestive of ACS. (Level of Evidence:
C)</b></span></span></font></font></font></span></strong></p>
<div id="acd1e499" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e499"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Estimation
of the Level of Risk</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
medical history, physical examination, ECG, and biochemical cardiac
marker measurements in patients with symptoms suggestive of ACS at
the time of initial presentation can be integrated into an estimate
of the risk of death and nonfatal cardiac ischemic events. An
estimation of the level of risk is a multivariable problem that
cannot be simply quantified. Table 1&nbsp;is illustrative of the
general relationships between clinical and ECG findings and the
categorization of patients into those at a low, an intermediate, or a
high level of risk of events.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Because
patients with new or severe ischemic discomfort are at an increased
risk of cardiac death and nonfatal ischemic events, an assessment of
the prognosis should set the pace of initial evaluation and
treatment. An estimation of risk is useful in (1) selection of the
site of care (coronary care unit, monitored step-down unit, or
outpatient setting) and (2) selection of therapy, especially platelet
glycoprotein (GP) IIb/IIIa inhibitors (see Section III. B) and
coronary revascularization (see Section IV). For all modes of
presentation of an ACS, a strong relationship exists between
indicators of the likelihood of ischemia due to CAD and prognosis.
Therefore, an assessment of the likelihood of CAD is the starting
point for determination of the prognosis of patients who present with
symptoms that are suggestive of an ACS. Other important elements for
prognostic assessment are the tempo of the patient’s clinical
course, which relates to the short-term risk of future cardiac
events, principally AMI, and the patient’s likelihood of survival
should an acute ischemic event occur.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
5 most important factors from the initial history that relate to the
likelihood that the patient is experiencing an episode of ischemia
due to CAD are (1) the nature of the symptoms, (2) a prior history of
CAD, (3) age, (4) sex, and (5) the number of traditional risk factors
that are present for CAD. Patients with UA may have discomfort that
has all of the qualities of typical angina except that the episodes
are more severe and prolonged, may occur at rest, or may be
precipitated by less exertion than was previously necessary.</font></font></font></p>
<div id="acd1e507" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e507"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Recommendation
for the Diagnosis of Noncardiac Causes of Symptoms</font></font></font></h5>
<div id="acd1e509" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e509"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Class
I</font></font></font></h5>
<p style="orphans: 2; widows: 2"><strong><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><b>1.
The initial evaluation of the patient with suspected ACS should
include a search for noncoronary causes that could explain the
development of symptoms. (Level of Evidence: C)</b></span></span></font></font></font></span></strong></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Information
from the initial history, physical examination, and ECG will enable
the physician to recognize and exclude from further assessment
patients classified as “not having ischemic discomfort.” This
includes patients with noncardiac pain and patients with cardiac pain
that is not caused by myocardial ischemia. The remaining patients
should undergo a more complete evaluation of secondary causes of UA
that might alter management. In patients with secondary angina,
factors that increase myocardial oxygen demand or decrease oxygen
delivery to the heart may provoke or exacerbate ischemia in the
presence of significant underlying CAD.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
major objectives of the physical examination are to identify
potential precipitating causes of myocardial ischemia (eg,
uncontrolled hypertension or thyrotoxicosis) and evidence of other
cardiac disease (eg, aortic stenosis or hypertrophic cardiomyopathy),
and comorbid conditions (eg, pulmonary disease) and to assess the
hemodynamic impact of the ischemic event.</font></font></font></p>
<div id="acd1e518" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e518"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Assessment
of Risk of Death in Patients With UA/NSTEMI</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">The
AHCPR guidelines “Unstable Angina: Diagnosis and Management”
identified low-risk UA patients as those&nbsp;<i>without</i>&nbsp;rest
or nocturnal angina and with normal or unchanged ECGs. High-risk
patients were identified as those with pulmonary edema; ongoing rest
pain for &gt;20 minutes; angina with S<font size="1" style="font-size: 7pt">3</font>&nbsp;gallop,
rales, or new or worsening mitral regurgitation murmur; hypotension;
or dynamic ST-segment change of ≥1 mm. Patients without low- or
high-risk features were termed to be at intermediate risk. The
present guidelines endorse these principles (Table 1) but indicate
that a rapid tempo of angina, a prior MI, and elevation of the
cardiac-specific troponin level are also strong predictors of the
risk of an adverse outcome. The&nbsp;<i>tempo of angina</i>&nbsp;is
characterized by an assessment of changes in the duration of
episodes, their frequency, and the anginal threshold.</font></font></font></p>
<div id="acd1e532" dir="ltr"><p style="orphans: 2; widows: 2"><br/>
<br/>

	</p>
</div>
<h5 class="western" style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2; margin-top: 0in; margin-bottom: 0in"><a name="d1e532"></a>
<font color="#000000"><font face="HelveticaNeueBoldCondensed, HelveticaNeue-Bold-Condensed, Helvetica Neue Bold Condensed, HelveticaNeue-CondensedBold, HelveticaNeueBold, HelveticaNeue-Bold, Helvetica Neue Bold, HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosCnBold, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Tools
for Risk Stratification</font></font></font></h5>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Although
imperfect, the 12-lead ECG lies at the center of the decision pathway
for the evaluation and management of patients with ischemic
discomfort. A recording made during an episode of the presenting
symptoms is particularly valuable. Importantly, transient ST-segment
changes (≥0.05 mV) that develop during a symptomatic episode at
rest and that resolve when the patient becomes asymptomatic strongly
suggest acute ischemia and a very high likelihood of underlying
severe CAD.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">CK-MB
has until recently been the principal serum cardiac marker used in
the evaluation of ACS. Despite its common use, CK-MB has several
limitations (Table 2). Low levels of CK-MB in the blood of healthy
individuals limit its specificity for myocardial necrosis. CK-MB
levels may also be elevated with severe damage of skeletal muscle.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Monoclonal
antibody–based immunoassays have been developed to detect
cardiac-specific TnT (cTnT) and cardiac-specific TnI (cTnI). Because
cTnT and cTnI are not detected in the blood of healthy individuals,
the cutoff value for elevated cTnT and cTnI levels may be set to
slightly above the upper limit of the assay of a normal healthy
population, leading to the terms “minor myocardial damage” or
“microinfarction” for patients with detectable troponin but no
CK-MB in the blood. It is estimated that ≈30% of patients who
present with rest pain without ST-segment elevation and would
otherwise be diagnosed as having UA because of a lack of CK-MB
elevation actually have NSTEMI when assessed with cardiac-specific
troponin assays.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2"><a name="F1R"></a>
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Elevated
levels of cTnT or cTnI convey prognostic information beyond that
supplied by the clinical characteristics of the patient, the ECG at
presentation, and a predischarge exercise test. Furthermore, among
patients without ST-segment elevation and normal CK-MB levels,
elevated cTnI or cTnT concentrations identify those at an increased
risk of death. Finally, there is a quantitative relationship between
the quantity of cTnI or cTnT that is measured and the risk of death
in patients who present with UA/NSTEMI (Figure 1). Patients who
present without ST-segment elevation and have elevated
cardiac-specific troponin levels may receive a greater treatment
benefit from platelet GP IIb/IIIa inhibitors and low-molecular-weight
heparin (LMWH).</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">Table
2&nbsp;provides a comparison of the advantages and disadvantages of
various cardiac markers for the evaluation and management of patients
with suspected ACS but without ECG ST-segment elevation. The
troponins offer greater diagnostic sensitivity due to their ability
to identify patients with lesser amounts of myocardial damage.
Nevertheless, these lesser amounts of damage are associated with a
high risk in patients with ACSs, because they are thought to
represent microinfarctions that result from microemboli from an
unstable plaque. Cardiac-specific troponins are gaining acceptance as
the primary biochemical cardiac marker in ACS. Although not quite as
sensitive or specific as the troponins, CK-MB by mass assay remains a
very useful marker for the detection of more than minor myocardial
damage. A normal CK-MB level, however, does not exclude the minor
myocardial damage and its attendant risk of adverse outcomes
detectable with cardiac-specific troponins. Because of its poor
cardiac specificity in the setting of skeletal muscle injury and its
rapid clearance from the bloodstream, myoglobin should not be used as
the&nbsp;<i>only</i>&nbsp;diagnostic marker for the identification of
patients with NSTEMI, but its early appearance with myocardial injury
makes its absence quite useful in ruling out myocardial necrosis.</font></font></font></p>
<p style="font-variant: normal; letter-spacing: normal; font-style: normal; font-weight: normal; orphans: 2; widows: 2">
<font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt">When
a central laboratory is used to measure biochemical cardiac markers,
results should be available within 60 minutes and preferably within
30 minutes. Point-of-care systems, if implemented at the bedside,
have the advantage of reducing delays due to transportation and
processing in a central laboratory and can eliminate delays due to
the lack of availability of central laboratory assays at all hours.
These advantages of point-of-care systems must be weighed against the
need for stringent quality control and appropriate training of ED
personnel in assay performance.</font></font></font></p>
<p style="orphans: 2; widows: 2"><span style="font-variant: normal"><font color="#000000"><font face="HelveticaNeue, Helvetica Neue, HelveticaNeueRoman, HelveticaNeue-Roman, Helvetica Neue Roman, TeXGyreHerosRegular, Helvetica, Arial, serif"><font size="2" style="font-size: 9pt"><span style="letter-spacing: normal"><span style="font-style: normal"><span style="font-weight: normal">Given
the increasing interest in the hypothesis that destabilization of
atherosclerotic plaques may result from inflammatory processes,
several groups have evaluated markers of the acute phase of
inflammation such as CRP in patients with UA. Patients who do not
have biochemical evidence of myocardial necrosis but have an elevated
CRP level appear to be at increased risk of an adverse outcome,
especially those whose CRP levels are markedly elevated.</span></span></span></font></font></font></span></p>
</body>
</html>